Cheshire, UK--(Marketwire - November 26, 2007) -
Protherics PLC
Notification of Directors' Interests
London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, announces that, on 23 November 2007, a conditional
right to receive 157,980 ordinary shares in Protherics ("Ordinary Shares") was
awarded to Saul Komisar, President of Protherics Inc., under the terms of the
Protherics PLC Long Term Incentive Plan (the "LTIP"). The award vests on the
third anniversary of the date of grant subject to the achievement of performance
conditions.
Protherics PLC also announces the grant, on 23 November 2007, of the following
options over Ordinary Shares in the Company under the terms of the LTIP:
Name Position Number of Options
Andrew Heath Chief Executive Officer 325,581
Rolf Soderstrom Finance Director 204,651
James Christie Operations Director 176,744
The options are exercisable between the third and tenth anniversary of the date
of grant at an exercise price of 2 pence per share, subject to the achievement
of performance conditions.
Following the above grant, the Directors hold options or conditional awards over
the following number of Ordinary Shares:
Andrew Heath 4,245,142
Rolf Soderstrom 627,727
James Christie 1,564,754
Saul Komisar 1,271,081
The current issued ordinary share capital of the Company is 339,696,822 shares.
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange